Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy
Autore:
Braun, J; de Keyser, F; Brandt, J; Mielants, H; Sieper, J; Veys, E;
Indirizzi:
Rheumazentrum Ruhrgebiet, D-44652 Herne, Germany Rheumazentrum RuhrgebietHerne Germany D-44652 t, D-44652 Herne, Germany Free Univ Berlin, Dept Gastroenterol & Rheumatol, D-1000 Berlin, Germany Free Univ Berlin Berlin Germany D-1000 Rheumatol, D-1000 Berlin, Germany State Univ Ghent, Dept Rheumatol, B-9000 Ghent, Belgium State Univ Ghent Ghent Belgium B-9000 t Rheumatol, B-9000 Ghent, Belgium
Titolo Testata:
CURRENT OPINION IN RHEUMATOLOGY
fascicolo: 4, volume: 13, anno: 2001,
pagine: 245 - 249
SICI:
1040-8711(200107)13:4<245:NTOISI>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
REFRACTORY ANKYLOSING-SPONDYLITIS; RHEUMATOID-ARTHRITIS PATIENTS; ALPHA MONOCLONAL-ANTIBODY; REACTIVE ARTHRITIS; TNF-ALPHA; DISEASE-ACTIVITY; INFLIXIMAB; TRIAL; SULFASALAZINE; SECRETION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
46
Recensione:
Indirizzi per estratti:
Indirizzo: Braun, J Rheumazentrum Ruhrgebiet, Landgrafenstr 15, D-44652 Herne, Germany Rheumazentrum Ruhrgebiet Landgrafenstr 15 Herne Germany D-44652
Citazione:
J. Braun et al., "New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy", CURR OP RH, 13(4), 2001, pp. 245-249

Abstract

Tumor necrosis factor-alpha is a major effector and regulatory cytokine, which seems to have an outstanding position in rheumatic and other inflammatory states. Because TNF-alpha has been detected in the inflamed gut and sacroiliac joints of patients with chronic inflammatory bowel diseases and spondyloarthritides, like ankylosing spondylitis, there was need for studies of the efficacy of the modern biologic anti-TNF agents infliximab and etanercept in these diseases. Infliximab is approved for the treatment of Crohn disease. In addition, there are now also positive data for infliximab in thetreatment of ankylosing spondylitis and for etanercept and infliximab in the treatment of psoriatic arthritis. (C) 2001 Lippincott Williams & Wilkins, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/09/20 alle ore 12:55:29